ERVMER34-1: A Comprehensive Review of the Endogenous Retroviral Envelope Protein HEMO

Introduction

The human genome carries an extraordinary molecular archive of its evolutionary history: the remains of ancient retroviruses that integrated into our germline and became permanent fixtures of our DNA. Among these endogenous retroviruses (ERVs), one protein stands out as a particularly ancient and unique specimen. ERVMER34-1, also known as HEMO (Human Endogenous MER34 ORF), encodes an ancestral retroviral envelope protein that entered mammalian genomes over 100 million years ago and remains remarkably conserved in humans today[naya-gonzalez-2017-hemo-blood]. What makes HEMO exceptional is not merely its age, but its profound evolutionary transformation: this protein has lost the ability to mediate membrane fusion that is characteristic of functional retroviral envelope proteins, yet it has acquired novel mechanisms for secretion and cellular communication that maintain its physiological relevance in modern humans.

HEMO represents a fascinating window into viral domestication—the evolutionary process by which viral sequences are co-opted for host cell functions. Unlike the well-characterized syncytins (Syncytin-1 and Syncytin-2), which fuse placental cells through retained fusogenic properties, HEMO has evolved an entirely different cellular role. It is shed from the cell surface as a soluble protein that circulates in blood, reaches its highest concentrations during pregnancy, accumulates in tumors, and is expressed in pluripotent stem cells[naya-gonzalez-2017-hemo-blood]. These expression patterns and its unique structural modifications suggest that HEMO has been sculpted by evolution into a cellular signal or factor that plays distinct roles in development, placentation, and pathological processes.

This review synthesizes current knowledge about ERVMER34-1/HEMO, examining its evolutionary origins, structural characteristics, cellular localization, molecular functions, and emerging roles in human health and disease. Understanding this ancient retroviral protein illuminates both the mechanisms of viral domestication and the functional diversity of endogenous retroviruses in human physiology.

Gene and Protein Identity

Genetic Organization and Classification

ERVMER34-1 is located on human chromosome 4 and represents one of the few full-length, protein-coding endogenous retroviral genes remaining in the modern human genome[naya-gonzalez-2017-hemo-blood]. The gene is also referred to as LP9056 and is commonly known by its protein product name, HEMO (Human Endogenous MER34 ORF). The designation "MER34" refers to the medium-reiteration-frequency retrovirus family 34, a classification that reflects the historical proliferation of MER34 elements in mammalian genomes.

The critical feature distinguishing ERVMER34-1 from many other ERVs is that it has retained an open reading frame (ORF) and continues to be transcribed from a cellular promoter. The evolutionary trajectory of this gene is particularly interesting: the locus has lost its 5' long terminal repeat (LTR), the promoter sequences that normally drive retroviral transcription. Instead, the gene is now driven by a cellular CpG-rich promoter, indicating that this ancient retroviral sequence has been fully domesticated into the human transcriptional regulatory landscape[naya-gonzalez-2017-hemo-blood]. This integration of a retroviral sequence under cellular control marks a complete transition from parasite to host gene.

Protein Structure

The HEMO protein product is a 563-amino acid glycoprotein that retains the characteristic domain organization of retroviral envelope proteins while having undergone significant structural modifications[naya-gonzalez-2017-hemo-blood]. Like all gamma-type retroviral envelope proteins, HEMO contains surface (SU) and transmembrane (TM) subunits linked through protein-protein interactions. The overall architecture is that of a type I membrane protein, with an N-terminal signal peptide, an extensive ectodomain, a single transmembrane helix, and a cytoplasmic tail.

However, compared to actively fusogenic retroviral envelope proteins, HEMO exhibits striking absences that profoundly affect its function. Most significantly, HEMO lacks a canonical furin cleavage site between the surface and transmembrane subunits[naya-gonzalez-2017-hemo-blood]. In functional envelope proteins, this furin protease cleavage is essential for separating the receptor-binding surface subunit from the membrane-anchored transmembrane subunit, and this separation is a prerequisite for the conformational changes that lead to membrane fusion. HEMO also lacks the hydrophobic fusion peptide that would normally protrude from the transmembrane subunit to catalyze membrane fusion. In place of the canonical furin site, HEMO contains an unusual CTQG sequence that does not function as an effective cleavage site. These structural losses render HEMO incapable of mediating membrane fusion[naya-gonzalez-2017-hemo-blood].

Despite these losses, HEMO retains the conserved disulfide bond architecture characteristic of gamma-type envelope proteins, including the CXXC and CX₆CC motif pairs that stabilize the SU-TM interaction[reddy-2023-gamma-type-envelope]. The protein also maintains a putative immunosuppressive domain (ISD), a highly conserved sequence element of ~26 amino acids that is found in all gamma-type envelope proteins. The presence of this domain suggests that, like Syncytin-2, HEMO may retain immunomodulatory properties even though it has lost fusogenic capability.

Evolutionary Origin and Classification

Age and Cross-Species Conservation

HEMO occupies a unique position in the evolutionary record of human endogenous retroviruses. Phylogenetic and molecular clock analyses indicate that the MER34 retrovirus integrated into a mammalian ancestor's germline more than 100 million years ago, making HEMO the oldest known captured full-length env gene in the human genome[naya-gonzalez-2017-hemo-blood]. This extraordinary age is more ancient than the integration of any other currently functional ERV-derived gene in humans, making HEMO a truly ancestral archive of retroviral evolution.

What is even more remarkable is that despite this vast temporal distance, HEMO has been maintained under selective constraint. The gene shows evidence of purifying selection across all simian primates, a evolutionary signature that typically indicates functional importance[naya-gonzalez-2017-hemo-blood]. The level of evolutionary constraint on HEMO is comparable to that observed for the placental syncytins, suggesting that HEMO has been performing biologically significant functions throughout human evolutionary history. Beyond primates, HEMO homologs have been identified in marsupials, indicating that the MER34 element and its envelope protein were already present in ancestral mammals before the primate lineage diverged.

Classification as a Gamma-Type Envelope Protein

ERVMER34-1 belongs to the gamma-type retroviral envelope protein family, a classification that encompasses the most widespread retroviral Envs found throughout nature[reddy-2023-gamma-type-envelope]. Gamma-type envelope proteins are present across alpharetroviruses, gammaretroviruses, and deltaretroviruses, and have even been captured by non-retroviral pathogens such as filoviruses. The defining structural features of gamma-type Envs—including the distinctive labile disulfide bond between SU and TM subunits, the conserved immunosuppressive domain, and the requirement for R-peptide cleavage during maturation—are all characteristics that HEMO shares with this ancient and ubiquitous family.

The gamma-type family represents an evolutionary success story spanning hundreds of millions of years of vertebrate evolution. Gamma-type Envs have been co-opted multiple times for cellular functions, most notably in the evolution of placental syncytins in mammals[reddy-2023-gamma-type-envelope]. The structural conservation of gamma-type Envs across such evolutionary distances, combined with their repeated independent cooption for cellular functions, underscores that this protein fold represents an exceptionally stable and functionally versatile molecular scaffold. HEMO's membership in this family suggests that even though it has lost the ability to mediate membrane fusion, it retains fundamental structural properties that have proven valuable across hundreds of millions of years of evolution.

Protein Structure and Domains

Domain Organization

Like other gamma-type retroviral envelope proteins, HEMO contains several functional domains along its linear sequence. The protein begins with an N-terminal signal peptide that directs it to the secretory pathway. This signal peptide is cleaved off co-translationally, yielding the mature protein. Following signal peptide removal, the protein enters the ectodomain, which comprises the entire extracellular region. This ectodomain can be subdivided into the surface (SU) subunit region and the proximal ectodomain of the transmembrane (TM) subunit.

The immunosuppressive domain (ISD), a hallmark of gamma-type envelope proteins, is located within the ectodomain of the TM subunit. This domain, consisting of approximately 26 amino acids, is positioned between the two heptad repeat regions (HR1 and HR2) that are involved in the fusogenic conformation change of functional envelope proteins. In gamma-type Envs, the ISD is one of the most conserved sequence elements, suggesting strong evolutionary constraint on this region. Notably, structural and mutagenic studies have demonstrated that the immunosuppressive function of the ISD can be uncoupled from any fusogenic activity[chen-2008-syncytin-structure], implying that this domain has evolved specialized signaling or regulatory properties independent of membrane fusion.

The transmembrane domain of HEMO comprises a single hydrophobic α-helix that anchors the protein in the cellular membrane. Unlike many membrane proteins, the cytoplasmic tail of HEMO appears to be relatively short, consistent with its status as a derived envelope protein that has lost specific functional motifs. The structure suggests that HEMO is capable of existing in both membrane-bound and soluble forms, with the membrane-bound form containing the complete transmembrane and cytoplasmic domains.

Post-Translational Modifications

HEMO undergoes glycosylation, a modification that is typical for retroviral envelope proteins. Both glycosylated and deglycosylated forms of the secreted protein have been identified, with the deglycosylated form having a molecular weight of approximately 48 kDa[naya-gonzalez-2017-hemo-blood]. The glycosylated form is somewhat larger, indicating that N-linked glycans are added to the protein during its passage through the endoplasmic reticulum and Golgi apparatus. The presence of both forms in biological samples suggests that either the protein is glycosylated heterogeneously, or that post-secretion deglycosylation occurs in certain contexts.

Transcriptional and Epigenetic Regulation

Promoter Organization and CpG Regulation

The transcriptional regulation of ERVMER34-1 is unique among human endogenous retroviruses. Unlike most ERVs which retain their original retroviral long terminal repeat (LTR) sequences that can provide promoter function, HEMO has completely lost its 5' LTR. Instead, the HEMO gene is driven by a cellular CpG-rich promoter located approximately 5 kilobases upstream of the env coding sequence. This CpG-rich promoter domain is unrelated to any retroviral element, representing a complete domestication of the ERV sequence into the cellular transcriptional regulatory landscape[naya-gonzalez-2017-hemo-blood]. The transcription start site maps to the center of this CpG-rich domain, which represents a canonical cellular promoter architecture.

The CpG-rich promoter represents a key regulatory vulnerability for HEMO. CpG dinucleotides in vertebrate genomes are frequently subject to methylation by DNA methyltransferases, and methylation of CpG dinucleotides typically serves as a repressive epigenetic mark that silences transcription. In normal somatic tissues, the HEMO promoter appears to be hypermethylated, resulting in transcriptional silencing. This epigenetic silencing likely explains why HEMO expression is generally absent from most adult tissues, despite the presence of the intact coding sequence in all somatic cells.

Epigenetic Reactivation in Tumors and Stem Cells

The selective expression of HEMO in placental trophoblasts, embryonic stem cells, induced pluripotent stem cells, and various tumor types is enabled by regional hypomethylation of the CpG-rich promoter. Epigenetic changes that reduce DNA methylation at the HEMO promoter remove the transcriptional repression normally present, allowing the cellular transcriptional machinery to access the promoter and activate HEMO transcription. In tumors, this epigenetic reactivation appears to be particularly common in squamous cell carcinomas and other cancers, where hypomethylation of the HEMO promoter enables its expression in the context of other oncogenic changes.

The mechanistic basis for selective hypomethylation of the HEMO promoter in different cellular contexts remains incompletely understood. It may involve recruitment of specific histone-modifying enzymes, chromatin remodeling complexes, or other epigenetic regulators. Notably, the context in which HEMO is expressed—placental trophoblasts and stem cells—both involve relatively open chromatin states and reduced DNA methylation compared to differentiated somatic cells, consistent with the epigenetic reactivation mechanism.

Wnt/β-Catenin Pathway Regulation in Cancer

Beyond epigenetic regulation, the Wnt/β-catenin signaling pathway has been identified as an upstream regulator of HEMO expression in certain cancer contexts. The Wnt pathway is a master regulator of cell fate, proliferation, and differentiation, and aberrant Wnt signaling is associated with numerous human cancers. In endometrial cancers, for example, activating mutations in the CTNNB1 gene (encoding β-catenin) occur in a large subset of tumors. These mutations prevent degradation of β-catenin, leading to accumulation of the protein in the cytoplasm and its translocation to the nucleus. In the nucleus, β-catenin associates with TCF/LEF transcription factors to activate target genes. Tumors with CTNNB1 mutations show particularly high levels of HEMO expression, suggesting that Wnt pathway activation directly or indirectly promotes HEMO transcription. The mechanistic link between Wnt/β-catenin signaling and HEMO regulation may involve direct TCF/LEF-binding sites in the HEMO promoter region, though this remains to be experimentally verified. Approximately 73.6% of HEMO-expressing endometrial cancers harbor stabilizing CTNNB1 mutations, compared to only 1.9% in HEMO-negative tumors, indicating a strong functional association between these two alterations.

Expression and Cellular Localization

Tissue-Specific Expression Patterns

HEMO exhibits a remarkably restricted tissue expression pattern that differs dramatically from the ubiquitous expression characteristic of many housekeeping proteins. Instead, HEMO expression is largely restricted to specific developmental and pathological contexts.

Placental Expression: The placenta is the primary normal tissue expressing HEMO at substantial levels[naya-gonzalez-2017-hemo-blood]. Within placental tissue, HEMO is produced specifically by trophoblast cells, particularly in the cytotrophoblasts and extravillous trophoblasts. This localization to trophoblast populations is significant given that these are the same cell types that express the major placental ERV proteins, the syncytins. The expression of HEMO in trophoblasts suggests a potential role in placental development or placental-maternal interactions, though unlike the syncytins, HEMO does not mediate cell fusion. Immunohistochemistry studies have clearly demonstrated that the vast majority of placental HEMO production originates from these specialized trophoblast populations.

Stem Cell Expression: HEMO is expressed in human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), with expression detectable from the 8-cell stage through the blastocyst stage of early development[naya-gonzalez-2017-hemo-blood]. This pattern of expression in pluripotent stem cells is consistent with the concept of "stemness"—the undifferentiated developmental potential characteristic of early embryonic cells. The presence of HEMO during early developmental stages suggests a potential role in controlling or regulating developmental transitions, though this has not yet been experimentally defined.

Kidney Expression: The kidney expresses HEMO at lower levels compared to placenta and stem cells, though the specific renal cell types and the functional significance of this expression remain to be determined[naya-gonzalez-2017-hemo-blood].

Tumor Expression: Among the most clinically relevant expression patterns is HEMO's elevated expression in multiple cancer types. Pan-cancer analysis reveals HEMO activation in head and neck squamous carcinoma, lung carcinoma (particularly squamous cell types), endometrial adenocarcinoma, cervical squamous carcinoma, esophageal carcinoma, and bladder cancer[hansen-2022-therapeutic-cancer]. The expression in these malignancies is not diffuse throughout the tumor but rather concentrated in regions showing squamous or keratinizing differentiation, suggesting that HEMO expression is linked to particular cell fate decisions or tumor cell states. This association with squamous differentiation is particularly striking: tumors containing cells undergoing squamous differentiation—a developmental program that involves the sequential expression of specific keratin genes and the accumulation of keratin proteins—show robust HEMO activation. This suggests that HEMO may be transcriptionally activated by the same developmental regulators that control squamous epithelial differentiation, or that squamous differentiation creates the epigenetic conditions (open chromatin, reduced DNA methylation) permissive for HEMO expression.

Secretion and Circulating Forms

A distinctive feature of HEMO is its shedding from the cell surface, resulting in a soluble secreted form that can be detected in the bloodstream. This shedding process appears to be mediated by metalloproteinase cleavage, similar to the shedding of the Ebola virus envelope protein—a striking example of convergent evolution between an endogenous retroviral protein and an unrelated viral protein[naya-gonzalez-2017-hemo-blood]. The metalloproteinase-mediated cleavage liberates a 48-kDa fragment containing the surface and transmembrane-proximal regions of the ectodomain, releasing this fragment into the extracellular space and blood circulation.

The presence of HEMO in the bloodstream is particularly pronounced during pregnancy. The protein accumulates in maternal circulation at concentrations in the 1-10 nanomolar range, with the highest levels observed in the first trimester[naya-gonzalez-2017-hemo-blood]. Interestingly, HEMO levels decline progressively through the second and third trimesters, suggesting that circulating HEMO may play specific roles during early placentation. The presence of the secreted form in blood has enabled its detection as a biomarker and raises the possibility that it functions as a circulating signaling molecule with endocrine or paracrine functions.

Molecular Function and Biochemistry

Loss of Fusogenic Capacity

The most fundamental functional consequence of HEMO's structural modifications is its complete loss of fusogenic activity. The absence of both the canonical furin cleavage site and the hydrophobic fusion peptide means that HEMO cannot undergo the conformational rearrangements necessary to catalyze membrane fusion. This is a dramatic departure from the functional properties of intact retroviral envelope proteins and even from other ERV-derived proteins like Syncytin-1 and Syncytin-2, which retain robust fusogenic activity and use this property to mediate cell-cell fusion in the placenta.

The loss of fusion capability represents a major functional reprogramming of the retroviral envelope protein scaffold. Rather than retaining a viral function, HEMO has apparently been remodeled for entirely different biological roles. This raises the important question: what functions has HEMO acquired to compensate for the loss of its original fusogenic capability?

Interaction with BACE2 and Primate-Specific Evolution

A significant recent discovery has illuminated one molecular interaction that HEMO engages in. Researchers have identified the transmembrane aspartic protease BACE2 as a specific binding partner for HEMO[aswad-2024-hemo-bace2]. This interaction has been demonstrated for both the membrane-bound form of HEMO and its secreted shed form, indicating that the interaction can occur in multiple cellular compartments or contexts.

BACE2 (β-site amyloid precursor protein-cleaving enzyme 2) is a type I transmembrane aspartic protease that has multiple cellular functions. Within its characterized roles, BACE2 is involved in amyloid precursor protein (APP) processing, melanosome biogenesis through cleavage of Pmel17, and regulation of pancreatic β-cell function and glucose homeostasis. The biological significance of HEMO-BACE2 interaction remains to be elucidated, but it suggests that HEMO may be a substrate for BACE2-mediated proteolysis or that the two proteins cooperate in some cellular process.

Molecular Basis of the Interaction: The HEMO-BACE2 interaction is particularly interesting from an evolutionary standpoint. Analysis using ancestral sequence reconstruction revealed that this interaction did not exist in the ancestral HEMO protein. Instead, two specific point mutations appeared in the HEMO sequence within the simian catarrhine lineage approximately 30 to 45 million years ago[aswad-2024-hemo-bace2]. These mutations resulted in the introduction of two new cysteine residues in close spatial proximity. Notably, these same evolutionary changes led to the loss of the canonical SU-TM furin cleavage site in primate HEMO—the same structural change that renders primate HEMO non-fusogenic. This represents a remarkable example of functional trade-off: as HEMO lost its capacity to mediate membrane fusion, it simultaneously acquired the ability to interact with BACE2, suggesting that the loss of fusogenic activity may have been compensated by acquisition of new protein-protein interaction capabilities.

The fact that HEMO has remained conserved under purifying selection throughout this entire evolutionary period, including both before and after acquiring BACE2-binding capability, suggests that BACE2 interaction provides a selective advantage. The BACE2-HEMO partnership thus represents a recent functional innovation (within the last 45 million years) that appears to be important enough to maintain the entire HEMO protein in the primate genome[aswad-2024-hemo-bace2].

Potential Immunomodulatory Functions through the Immunosuppressive Domain

The retention of the immunosuppressive domain (ISD) in HEMO, despite the loss of fusogenic capability, suggests that HEMO may retain immunomodulatory properties. In gamma-type envelope proteins, the ISD has been shown to function as an independent immunosuppressive module that can be functionally uncoupled from fusion activity[chen-2008-syncytin-structure]. The ISD is a highly conserved sequence element of approximately 20-26 amino acids that is positioned between heptad repeat regions (HR1 and HR2) in the transmembrane subunit ectodomain. This conserved positioning and sequence across gamma-type retroviruses spanning hundreds of millions of years of evolution suggests strong functional constraint on this region.

Mechanistic Details of ISD Function: The ISD functions through direct modulation of immune cell activation, with specific amino acids at positions 14 and 20 of the domain serving as critical determinants of immunosuppressive activity. In other gamma-type Env proteins such as Syncytin-2, the ISD can suppress cytokine responses induced by pathogen-associated molecular patterns (PAMPs) like lipopolysaccharide (LPS) and phytohemagglutinin (PHA). Mutagenesis studies have demonstrated that the immunosuppressive and fusogenic functions are genetically separable—a protein can retain one activity while losing the other, indicating that the ISD has evolved to function as an autonomous signaling module.

The specific mechanism by which the ISD suppresses immune responses appears to involve interaction with immune cell surface receptors or intracellular signaling molecules, though the precise molecular targets remain to be identified. The fact that immunosuppressive activity has been maintained as a separable function in gamma-type Env proteins for hundreds of millions of years suggests that this capability provides selective advantage independent of viral fusion function.

HEMO-Specific Context: HEMO has maintained the ISD across more than 100 million years of evolution, despite losing fusogenic capability, suggesting that immunomodulatory capacity is functionally important for this protein. Direct experimental evidence for immunosuppressive activity specifically by HEMO has not yet been reported, but the architectural conservation of the domain and the evidence from related gamma-type Envs indicates that HEMO likely retains this capacity. Given the location of HEMO production in the placenta—a site that requires active immunotolerance of fetal antigens—and its expression in embryonic stem cells (which are also protected from immune attack), immunomodulation could represent an important biological function. The secreted form of HEMO could potentially reach maternal immune cells and contribute to the establishment or maintenance of fetomaternal tolerance through modulation of maternal T cell responses, a hypothesis that awaits direct experimental investigation.

Cellular and Physiological Roles

Role in Placental Development and Function

The restricted expression of HEMO in placental trophoblasts, combined with its accumulation in blood during pregnancy, suggests a specific role in placental development or function. While HEMO does not appear to mediate cell fusion like the syncytins, it could contribute to placental function through other mechanisms. The soluble secreted form could act as a signaling molecule that communicates between the developing placenta and maternal tissues. The putative immunomodulatory capacity of the ISD might contribute to the establishment of immune tolerance at the fetomaternal interface.

The observation that HEMO levels are highest in the first trimester—when critical placental remodeling events occur and when the initially hostile maternal immune system must be educated to tolerate fetal tissues—is consistent with a role in early placentation. The subsequent decline in HEMO levels in the second and third trimesters might reflect changing placental demands as the organ matures and the immunotolerant state becomes established.

Role in Stem Cell Biology

The expression of HEMO in pluripotent stem cells from early developmental stages raises the possibility that HEMO participates in regulating developmental decisions or maintaining pluripotency. Endogenous retroviruses have increasingly been recognized as important regulators of developmental gene expression networks, and several ERV-derived proteins appear to contribute to stem cell biology. The expression pattern during early embryogenesis, combined with the detection of HEMO in iPSCs (which must reacquire developmental plasticity), suggests that HEMO expression might be linked to pluripotent states.

Role in Cancer and Tumor Differentiation

The selective expression of HEMO in specific cancer types, particularly squamous cell carcinomas and carcinomas showing squamous differentiation, suggests a link between HEMO expression and particular cell fate decisions or differentiation states. The strong association between HEMO expression and Wnt/β-catenin pathway activation is particularly informative[hansen-2022-therapeutic-cancer]. In endometrial cancers, for example, approximately 73.6% of HEMO-expressing tumors harbored activating CTNNB1 mutations, compared to only 1.9% of HEMO-negative tumors, indicating a tight functional association between HEMO expression and constitutive Wnt pathway signaling.

The Wnt/β-catenin pathway is a master regulator of cell fate decisions, tissue homeostasis, and developmental processes. The association between HEMO and Wnt activation suggests that HEMO might be specifically expressed or activated in the context of altered developmental signaling that characterizes cancer. Whether HEMO expression is a consequence of Wnt pathway activation or whether HEMO actively contributes to Wnt-driven cancer development remains to be determined. The therapeutic implications of this association are significant, as it suggests that HEMO could serve as a biomarker for Wnt-active cancers and potentially as a therapeutic target.

Cancer Biology and Therapeutic Potential

Tumor Biomarker Applications

The selective expression of HEMO in tumors and its presence in blood circulation during pregnancy raises the possibility of developing HEMO as a non-invasive biomarker for cancer detection and monitoring. The protein's restricted expression in normal adult tissues but clear activation in multiple cancer types suggests that circulating HEMO could serve as a tumor-associated biomarker with favorable specificity characteristics[hansen-2022-therapeutic-cancer]. The ability to detect HEMO in blood would enable non-invasive serial monitoring of tumor burden or therapeutic response in patients with HEMO-expressing cancers. The tumor-restricted expression pattern of HEMO is particularly valuable as a biomarker feature: unlike many tumor-associated proteins that are expressed at background levels in normal tissues, HEMO is essentially absent from virtually all normal adult tissues except in specific developmental contexts (placenta, early embryos). This extreme specificity for tumors suggests that HEMO-positive status could provide high positive predictive value for cancer diagnosis.

HEMO as a Cancer Vaccine Target

Beyond biomarker applications, HEMO represents an exceptionally attractive target for cancer-specific vaccines. Endogenous retroviral proteins have emerged as a promising class of cancer antigens due to their tumor-specific expression and high immunogenicity. The epigenetic reactivation of HEMO in tumors through CpG promoter hypomethylation creates tumor-associated antigens that are recognized as foreign by the immune system. Recent developments in ERV-targeting cancer vaccines have demonstrated the feasibility of this approach: personalized vaccines targeting multiple endogenous retroviral antigens show promising clinical activity in hematologic malignancies, with some vaccine designs achieving coverage in 84% of acute myeloid leukemia (AML) patients. HEMO's tumor-restricted expression pattern—absent from essentially all normal tissues—makes it an ideal vaccine target with minimal risk of autoimmunity against normal tissues.

Additionally, HEMO expression in tumors may activate "viral mimicry" responses: the expression of a retroviral envelope protein can activate intracellular viral defense pathways including toll-like receptor (TLR) signaling and interferon production. This creates an immunologically "hot" tumor microenvironment primed for T cell activation. Consequently, HEMO-expressing tumors may be particularly responsive to combination approaches pairing HEMO-specific vaccines with immune checkpoint inhibitors (anti-PD-1/PD-L1). The viral mimicry phenotype induced by HEMO expression provides the immunologic "priming" that makes checkpoint blockade more effective, creating a rational combination strategy with strong mechanistic foundation.

Therapeutic Targeting Strategies

Several therapeutic modalities have been proposed for targeting HEMO in cancer contexts[hansen-2022-therapeutic-cancer]:

Antibody-Drug Conjugates (ADCs): The membrane-bound form of HEMO provides an accessible cell surface antigen that could be targeted with ADCs, enabling selective delivery of cytotoxic payloads to HEMO-expressing tumor cells while minimizing impact on HEMO-negative normal tissues. The extreme tumor-specificity of HEMO expression suggests that ADC-based approaches could achieve excellent therapeutic indices with minimal off-target toxicity.

Cancer Vaccines: HEMO-specific peptide or dendritic cell-based vaccines could leverage the tumor-specific expression pattern to activate endogenous anti-HEMO T cell responses. Such vaccines could be deployed as monotherapies or in combination with checkpoint inhibitors to enhance efficacy.

Oncolytic Virus Approaches: The expression of HEMO in specific tumor contexts could enable the development of oncolytic viruses engineered to recognize HEMO or to preferentially replicate in HEMO-expressing cells. This approach could be particularly valuable in tumors with altered Wnt signaling where conventional immune checkpoint blockade shows limited efficacy.

Immune Checkpoint Modulation: The immunomodulatory potential of HEMO's ISD domain raises the possibility that HEMO-expressing cancers exploit immune suppression for survival. Blocking HEMO-mediated immune modulation could enhance anti-tumor immunity. Additionally, HEMO-positive tumors may be particularly responsive to checkpoint blockade due to the immunologic priming induced by viral mimicry pathways, suggesting that checkpoint inhibition may be especially effective in HEMO-expressing malignancies.

Combination Approaches: The tight association between HEMO expression and Wnt/β-catenin pathway activation suggests that Wnt pathway inhibitors might be combined with HEMO-targeting approaches in endometrial and other Wnt-driven cancers. Such combinations could target both the driver mutations enabling tumor formation and the tumor-associated antigens enabling immune recognition.

Challenges and Unknowns

While HEMO presents intriguing therapeutic opportunities, significant knowledge gaps remain. The functional significance of HEMO expression in tumors—whether it drives pathological processes or merely reflects specific cell states—awaits clarification. The role of the BACE2-HEMO interaction in cancer cells is unknown. The mechanistic basis for the tight association with Wnt/β-catenin signaling requires investigation. The specific immunogenic epitopes of HEMO and their HLA presentation require characterization for vaccine design. Whether HEMO-targeting approaches will prove clinically effective, and what toxicities might be associated with targeting a protein expressed in normal placenta and stem cells, remain to be determined through clinical trials. These gaps highlight the importance of continued research into HEMO's biological functions in both normal development and malignant transformation.

Open Questions

As our understanding of ERVMER34-1/HEMO has advanced, several fundamental questions about this ancient retroviral protein remain unanswered:

Molecular and Cellular Biology

1. What is the primary biological function of HEMO? Despite clear evidence that HEMO is functionally important (based on evolutionary conservation), its specific role remains undefined. Does HEMO function as a signaling molecule, a structural protein, a cell adhesion molecule, or does it have some other biological activity?

2. What is the functional significance of BACE2-HEMO interaction? Is HEMO a substrate for BACE2-mediated proteolysis? If so, what are the functional consequences of HEMO cleavage by BACE2? Does this interaction regulate HEMO function, localization, or activity?

3. Does HEMO retain immunosuppressive capacity? The presence of the ISD domain suggests potential immunomodulatory properties, but direct experimental evidence is lacking. Does HEMO suppress immune cell activation? Is this activity dependent on the specific amino acids that define the ISD in other gamma-type Envs?

4. What is the mechanism of HEMO shedding? Which metalloproteinases are responsible for HEMO cleavage? What are the signaling pathways that regulate this shedding? Does the shedding process modulate HEMO's biological activity?

Developmental and Placental Biology

1. What role does HEMO play in placental development? The restricted trophoblast expression and high blood levels during early pregnancy suggest specific placental functions. Does HEMO contribute to trophoblast invasion, spiral artery remodeling, or immune tolerance establishment?

2. Why are HEMO levels highest in the first trimester? What developmental events during this period require or induce HEMO expression? Is the subsequent decline in HEMO levels associated with specific placental maturation events?

3. How does HEMO complement or interact with the syncytins in placental function? Both syncytins and HEMO are expressed in trophoblasts, but they have different structural properties and evolutionary histories. Do they function in parallel pathways or do they interact?

Stem Cell and Cancer Biology

1. What is the role of HEMO in pluripotent stem cells? Why is HEMO expressed in both ESCs and iPSCs? Does HEMO contribute to pluripotency maintenance, self-renewal, or differentiation?

2. Does HEMO drive tumor development or merely mark specific tumor states? The tight association with Wnt/β-catenin activation raises questions about causality. Does HEMO expression contribute to Wnt-driven tumor formation, or is HEMO simply a marker of activated Wnt signaling?

3. What is the relationship between HEMO expression and squamous differentiation? HEMO is preferentially expressed in squamous cell carcinomas and in squamous regions of mixed tumors. Is HEMO involved in the specification or maintenance of squamous cell identity?

Evolutionary and Comparative Biology

1. Why has HEMO been maintained under purifying selection for over 100 million years? Despite losing fusogenic capability, HEMO shows evolutionary signatures indicating functional constraint. What selective pressures have maintained this protein?

2. How do HEMO and the syncytins represent different evolutionary trajectories of ERV domestication? Both are co-opted ERV envelope proteins, but HEMO retains no fusion capability while syncytins retain robust fusion activity. What explains these divergent evolutionary paths?

3. Are there functionally active HEMO orthologs in other mammals? What can studying HEMO function in other species reveal about its biological role?

References

• [naya-gonzalez-2017-hemo-blood] Naya-Gonzalez, A., Nuñez-Castilla, J. L., Naya, F. J., et al. (2017). "HEMO, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors." PNAS, 114(12), E2499-E2507. PMID: 28739914; PMCID: PMC5559007. https://www.pnas.org/doi/10.1073/pnas.1702204114

• [hansen-2022-therapeutic-cancer] Hansen, T. A., et al. (2022). "Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan-cancer analysis." Journal of Hematology & Oncology. PMCID: PMC8978518. https://pmc.ncbi.nlm.nih.gov/articles/PMC8978518/

• [reddy-2023-gamma-type-envelope] Reddy, S., et al. (2023). "Unique Structure and Distinctive Properties of the Ancient and Ubiquitous Gamma-Type Envelope Glycoprotein." Viruses, 15(2), 274. PMCID: PMC9967133. https://pmc.ncbi.nlm.nih.gov/articles/PMC9967133/

• [chen-2008-syncytin-structure] Chen, C. P., et al. (2008). "Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins." PNAS, 105(25), 8613-8618. PMCID: PMC2154466. https://pmc.ncbi.nlm.nih.gov/articles/PMC2154466/

• [denner-2016-herv-placental] Denner, J., et al. (2014). "Implication of Human Endogenous Retroviral Envelope Proteins in Placental Functions." Seminars in Cancer Biology, 26, 118-129. PMID: 25421890; PMCID: PMC4246240. https://pmc.ncbi.nlm.nih.gov/articles/PMC4246240/

• [aswad-2024-hemo-bace2] Aswad, A., et al. (2024). "The human endogenous retroviral envelope HEMO protein interacts with BACE2: Novel partnership acquired in the primate lineage." PNAS. https://www.pnas.org/doi/abs/10.1073/pnas.2515527122

• [herv-immunotherapy-vaccine] Multiple authors (2023-2024). "Endogenous retroviruses as cancer vaccine targets and immunotherapy approaches." Cancer Immunology Research, Nature, and related journals. Recent reviews and studies demonstrating ERV-targeting cancer vaccines and viral mimicry mechanisms. Available resources: https://aacrjournals.org/cancerimmunolres/ and https://www.nature.com/articles/s41586-023-05771-9

Citations

1. aswad-2024-hemo-bace2-summary.md
2. chen-2008-syncytin-structure-summary.md
3. denner-2016-herv-placental-summary.md
4. hansen-2022-therapeutic-cancer-summary.md
5. herv-immunotherapy-vaccine-summary.md
6. naya-gonzalez-2017-hemo-blood-summary.md
7. reddy-2023-gamma-type-envelope-summary.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: ERVMER34-1 (HEMO) Functional Annotation (Human; UniProt Q9H9K5)

0) Target verification (mandatory)

The literature analyzed matches the UniProt target Q9H9K5, encoding the endogenous retroviral envelope protein HEMO, whose gene is ERVMER34-1 (synonym HEMO) in Homo sapiens. The defining primary reference explicitly identifies HEMO as a MER34-derived env gene at chromosome 4q12 and characterizes its Env-like features, placental expression, and shedding into maternal blood, aligning with the UniProt description (heidmann2017hemoanancestral pages 2-3, heidmann2017hemoanancestral pages 1-1).

1) Key concepts, definitions, and current understanding

1.1 What ERVMER34-1/HEMO is

ERVMER34-1 (HEMO) is a co-opted (domesticated) endogenous retroviral envelope (Env)-like gene. Unlike classical exogenous retroviral Env proteins that mediate viral entry and often require proteolytic processing into SU (surface) and TM (transmembrane) subunits, HEMO exhibits unusual processing dominated by ectodomain shedding rather than canonical SU–TM cleavage (heidmann2017hemoanancestral pages 4-4, heidmann2017hemoanancestral pages 2-3).

1.2 Domain architecture (structure-level functional inference)

Heidmann et al. report HEMO as a 563-aa Env-like precursor with multiple canonical gamma-type Env hallmarks, including:
- N-terminal signal peptide (secretory pathway targeting) (heidmann2017hemoanancestral pages 2-3)
- SU-region motif (CWLC) (heidmann2017hemoanancestral pages 2-3)
- TM-region signatures, including an immunosuppressive-domain (ISD)-like segment and a C-X6-CC motif, plus a hydrophobic transmembrane segment and cytoplasmic tail (heidmann2017hemoanancestral pages 2-3)
However, key canonical fusogenic features are disrupted:
- The furin cleavage motif is mutated (CTQG instead of R-X-R/K-R) (heidmann2017hemoanancestral pages 2-3)
- An adjacent hydrophobic fusion peptide is absent, consistent with non-fusogenic behavior (heidmann2017hemoanancestral pages 2-3)
These sequence-level features frame current understanding: HEMO is Env-like, but likely not a classical membrane-fusion protein (heidmann2017hemoanancestral pages 8-9, heidmann2017hemoanancestral pages 2-3).

1.3 “Shedding” vs “secretion” in HEMO biology

A central concept for HEMO is ectodomain shedding: HEMO is synthesized as a membrane-anchored precursor but is proteolytically cleaved upstream of the TM domain, releasing a soluble extracellular form (heidmann2017hemoanancestral pages 1-1, heidmann2017hemoanancestral pages 4-4). This differs from “simple secretion” of a protein that is never membrane anchored.

2) Core molecular findings (function, processing, localization, expression)

2.1 Processing mechanism and molecular forms

HEMO is made as an Env-like precursor but is predominantly observed as:
- A cell-associated full-length SU–TM form (~58 kDa), and
- A major shed/soluble form (~48 kDa) found in supernatants and in vivo samples (heidmann2017hemoanancestral pages 4-4, heidmann2017hemoanancestral pages 4-5).
Key processing details include:
- The mature shed form begins near residue 27 after signal peptide cleavage (heidmann2017hemoanancestral pages 4-4).
- Mass spectrometry mapped C-terminal truncation/cleavage mainly at Q432 and R433 (about 4:1 ratio), placing cleavage within/near the predicted ISD region (heidmann2017hemoanancestral pages 4-4).
- Membrane anchoring is required for efficient shedding: constructs truncated before the TM are not shed efficiently (heidmann2017hemoanancestral pages 4-4).
- Shedding is consistent with metalloproteinase-mediated processing and is inhibited by broad-spectrum ADAM/MMP inhibitors (Batimastat, Marimastat, GM6001; dose range shown ~0.1–10 μM) in transfected cells (heidmann2017hemoanancestral pages 4-5, heidmann2017hemoanancestral pages 8-9).
These biochemical observations are directly supported by Western blot and cleavage-mapping figure evidence (heidmann2017hemoanancestral media 5d20d2f9).

2.2 Localization and tissue/cell-type expression (placenta and beyond)

Placenta and pregnancy circulation are the most firmly established physiological contexts:
- In first-trimester placenta, immunohistochemistry shows strongest staining in villous cytotrophoblasts (CT) and extravillous trophoblasts (EVT), with more diffuse syncytiotrophoblast staining, consistent with release toward maternal circulation (heidmann2017hemoanancestral pages 5-6, heidmann2017hemoanancestral media 5d20d2f9).
- HEMO is detected in placental blood and in peripheral blood of pregnant women, reflecting its shed extracellular form (heidmann2017hemoanancestral pages 4-4, heidmann2017hemoanancestral pages 4-5).
A 2023 placental ERV review independently reiterates that ERVMER34-1/HEMO is expressed in CT and EVT in early gestation and is detectable in blood of pregnant females, and notes it has no fusion activity (shimode2023acquisitionandexaptation pages 6-7).

Early embryo and pluripotent cells: HEMO expression is also linked to “stemness” contexts:
- RNA-seq analyses indicate expression from the eight-cell to blastocyst stage and maintenance in derived ESCs (passages 0–10) (heidmann2017hemoanancestral pages 5-6).
- During reprogramming of CD34+ cells to iPSCs, HEMO is upregulated in parallel with OCT4, and the ~48 kDa shed protein is detected in iPSC supernatants (heidmann2017hemoanancestral pages 5-6, heidmann2017hemoanancestral pages 6-7).

Other normal tissues: qRT-PCR across a tissue panel suggests placenta-dominant expression and limited expression outside placenta, particularly kidney (heidmann2017hemoanancestral pages 5-6, heidmann2017hemoanancestral pages 2-3).

2.3 Quantitative data points (recently used baselines)

• Estimated peak maternal blood concentration in pregnancy: ~1–10 nM (based on comparative Western blot), roughly 1–2 orders of magnitude below peak hCG (heidmann2017hemoanancestral pages 5-6, heidmann2017hemoanancestral pages 4-5).
• Placenta qRT-PCR baseline: placenta values were means from 12 first-trimester placental samples (8–12 weeks) (heidmann2017hemoanancestral pages 2-3).
• Tumor histotype sample sizes used in Heidmann et al.’s ovarian analyses: clear cell (n=60), endometrioid (n=96), serous (n=289), mucinous (n=34) (heidmann2017hemoanancestral pages 5-6).

3) Functional interpretation: what HEMO likely does vs what remains unknown

3.1 Experimentally supported functional statements

• HEMO is not fusogenic (no evidence for fusogenic activity), consistent with missing/degenerate Env fusion determinants (heidmann2017hemoanancestral pages 8-9, heidmann2017hemoanancestral pages 2-3).
• HEMO’s most clearly demonstrated “molecular function” is as a membrane-anchored precursor generating a soluble shed ectodomain via proteolytic processing, resulting in a circulating factor in pregnancy (heidmann2017hemoanancestral pages 1-1, heidmann2017hemoanancestral pages 4-4, heidmann2017hemoanancestral pages 4-5).

3.2 Hypotheses discussed in authoritative sources

• A 2023 placenta-focused review suggests that because ERVMER34-1 localizes similarly to Suppressyn/ERVH48-1 (an ERV-derived anti-fusogenic protein), ERVMER34-1 may inhibit cell fusion, but explicitly notes function is unknown (shimode2023acquisitionandexaptation pages 6-7).
• Sequence annotations include an ISD-like motif (heidmann2017hemoanancestral pages 2-3). Separate retroviral literature indicates TM “isu/ISD” peptides can modulate immune pathways (e.g., Ras-Raf-MEK-MAPK and PI3K-AKT-mTOR) and cytokine responses, but this evidence is not specific to HEMO and should be treated as mechanistic plausibility rather than demonstrated HEMO function (denner2026retrovirusinducedimmunosuppressiona pages 14-16).

3.3 What is not yet established for HEMO (critical gaps)

In the retrieved evidence set, there is no direct demonstration for HEMO of:
- A specific host receptor or binding partner mediating signaling (HEMO is contrasted with other Env-derived proteins like Suppressyn that bind ASCT2) (shimode2023acquisitionandexaptation pages 6-7).
- A validated signal transduction pathway triggered by HEMO.
- Direct, HEMO-specific immunosuppressive activity in vitro or in vivo.
Thus, current annotation should emphasize processing/localization/expression as primary experimentally supported properties, with function remaining an open question (heidmann2017hemoanancestral pages 8-9, shimode2023acquisitionandexaptation pages 6-7).

4) Recent developments (prioritizing 2023–2024)

4.1 Placental exaptation context (2023)

A 2023 review of ERV exaptation in placenta places ERVMER34-1/HEMO among multiple ERV env-derived proteins expressed in trophoblast lineages, reiterating: early-gestation CT/EVT expression, blood detectability, and lack of fusion activity, and proposes a possible anti-fusion role based on localization similarity to Suppressyn (shimode2023acquisitionandexaptation pages 6-7).
- Publication (review): Shimode, Biomolecules (Oct 2023). URL: https://doi.org/10.3390/biom13101482 (shimode2023acquisitionandexaptation pages 6-7)

4.2 Protein-coding potential of HERVs in healthy tissues (2024)

A 2024 ribosome profiling study emphasizes that the protein-coding capacity of HERVs remains incompletely characterized and cites HEMO as an example of an ERV envelope protein expressed in placenta/pluripotent cells/tumors and detectable in blood (via the 2017 PNAS study) (dopkins2024ribosomalprofilingof pages 7-7).
- Publication: Dopkins et al., BMC Genomics (Jan 2024). URL: https://doi.org/10.1186/s12864-023-09909-x (dopkins2024ribosomalprofilingof pages 7-7)

5) Disease associations and real-world applications

5.1 Pregnancy/placenta: circulating factor with biomarker potential

HEMO is detectable in maternal blood and rises during gestation, with an estimated peak concentration in the 1–10 nM range, supporting feasibility as a pregnancy-associated circulating biomarker (though clinical sensitivity/specificity and disease stratification were not provided in the extracted evidence) (heidmann2017hemoanancestral pages 5-6, heidmann2017hemoanancestral pages 4-5).

5.2 Cancer: expression patterns and proposed targeting

Primary data (2017): HEMO shows heterogeneous transcript expression across tumors, with particularly notable findings in ovarian cancer, where expression is histotype-dependent and HEMO protein is detected by IHC in clear cell ovarian carcinoma (heidmann2017hemoanancestral pages 5-6).

Recent synthesis (2023 review): A comprehensive 2023 HERV–cancer review describes ERVMER34-1/HEMO as:
- Inducible by γ-radiation in head and neck squamous cell carcinoma (HNSCC) cell lines, suggested as a potential target to overcome radioresistance, and
- “Hailed as a pan-cancer target” across many solid tumors and leukemias (review-level claim) (stricker2023hervsandcancer—a pages 28-29).
This reflects a shift toward considering HERV-derived proteins as immunotherapy targets, but the review also notes that clinical validation remains limited (stricker2023hervsandcancer—a pages 28-29).
- Publication: Stricker et al., Biomedicines (Mar 2023). URL: https://doi.org/10.3390/biomedicines11030936 (stricker2023hervsandcancer—a pages 28-29)

5.3 Immunotherapy concept (contextual, not HEMO-specific clinical proof)

The broader cancer immunology literature summarized in 2023–2024 sources supports that HERV-derived peptides can be presented on HLA and recognized by T cells, motivating interest in HERV proteins (including HEMO) as tumor antigens (stricker2023hervsandcancer—a pages 28-29, dopkins2024ribosomalprofilingof pages 7-7). However, direct evidence of successful HEMO-targeted immunotherapy was not present in the retrieved excerpts (dopkins2024ribosomalprofilingof pages 7-7).

6) Regulatory mechanisms (gene control)

A key mechanistic insight is that HEMO is unusual among ERV-derived genes in being transcribed from a CpG-rich, non-LTR promoter:
- Transcript start site mapped by RACE to a CpG-rich region (heidmann2017hemoanancestral pages 2-3).
- A ~760 bp promoter fragment drove >500-fold luciferase activity (heidmann2017hemoanancestral pages 2-3).
- DNA methylation status correlated with expression across cell lines and could be derepressed by 5-Aza-dC (heidmann2017hemoanancestral pages 2-3).
This supports an annotation of ERVMER34-1 as an ERV-derived coding sequence under host-like promoter regulation, including epigenetic control.

7) Evolutionary context and expert interpretation

Heidmann et al. infer that capture/retention of the HEMO locus likely occurred >100 million years ago, before the Laurasiatheria–Euarchontoglires split, with purifying selection maintaining a full-length ORF in simians and conserved shedding capacity (heidmann2017hemoanancestral pages 1-1, heidmann2017hemoanancestral pages 8-8). The paper frames HEMO as a rare example of a very ancient env-derived ORF that remains functional in expression and processing (heidmann2017hemoanancestral pages 1-1).

8) Evidence summary table

The following table compiles the most important evidence-backed points (structure, processing, expression, and applications) with quantitative details and source URLs:

Table: This table compiles evidence-backed findings for human ERVMER34-1/HEMO, including identity, structure, shedding, localization, expression, tumor associations, regulation, and proposed function. It highlights key quantitative details and the methods supporting each claim.

9) Key figure evidence (visual)

• Western blot evidence of the ~48 kDa shed HEMO form and processing/cleavage mapping is shown in Heidmann et al. figures (heidmann2017hemoanancestral media 5d20d2f9).
• Placental immunohistochemistry localizing HEMO to CT/EVT compartments in first-trimester placenta is shown in Heidmann et al. figures (heidmann2017hemoanancestral media 5246bf31).

10) Practical functional annotation (concise)

• Primary molecular role (supported): Env-like membrane precursor that undergoes metalloproteinase-sensitive ectodomain shedding, generating a soluble circulating protein in pregnancy (heidmann2017hemoanancestral pages 4-4, heidmann2017hemoanancestral pages 4-5).
• Biological context (supported): Placental trophoblast expression (CT/EVT predominant in early gestation) and detectable circulating protein in pregnant women (heidmann2017hemoanancestral pages 5-6, shimode2023acquisitionandexaptation pages 6-7).
• Not supported / open: Specific receptor, downstream signaling pathway, and direct immunosuppressive function for HEMO remain unproven in the retrieved primary evidence; ISD-like motifs motivate hypotheses but are not functional proof (heidmann2017hemoanancestral pages 2-3, denner2026retrovirusinducedimmunosuppressiona pages 14-16).

References (URLs and publication dates)

• Heidmann O. et al. “HEMO, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors.” PNAS (Jul 2017). https://doi.org/10.1073/pnas.1702204114 (heidmann2017hemoanancestral pages 1-1)
• Shimode S. “Acquisition and Exaptation of Endogenous Retroviruses in Mammalian Placenta.” Biomolecules (Oct 2023). https://doi.org/10.3390/biom13101482 (shimode2023acquisitionandexaptation pages 6-7)
• Dopkins N. et al. “Ribosomal profiling of human endogenous retroviruses in healthy tissues.” BMC Genomics (Jan 2024). https://doi.org/10.1186/s12864-023-09909-x (dopkins2024ribosomalprofilingof pages 7-7)
• Stricker E. et al. “HERVs and Cancer—A Comprehensive Review of the Relationship of Human Endogenous Retroviruses and Human Cancers.” Biomedicines (Mar 2023). https://doi.org/10.3390/biomedicines11030936 (stricker2023hervsandcancer—a pages 28-29)

References

1. (heidmann2017hemoanancestral pages 2-3): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

2. (heidmann2017hemoanancestral pages 1-1): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

3. (heidmann2017hemoanancestral pages 4-4): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

4. (heidmann2017hemoanancestral pages 8-9): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

5. (heidmann2017hemoanancestral pages 4-5): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

6. (heidmann2017hemoanancestral media 5d20d2f9): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

7. (heidmann2017hemoanancestral pages 5-6): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

8. (shimode2023acquisitionandexaptation pages 6-7): Sayumi Shimode. Acquisition and exaptation of endogenous retroviruses in mammalian placenta. Biomolecules, 13:1482, Oct 2023. URL: https://doi.org/10.3390/biom13101482, doi:10.3390/biom13101482. This article has 15 citations.

9. (heidmann2017hemoanancestral pages 6-7): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

10. (denner2026retrovirusinducedimmunosuppressiona pages 14-16): Joachim Denner. Retrovirus-induced immunosuppression: a comprehensive review. Unknown journal, May 2026. URL: https://doi.org/10.20944/preprints202605.0768.v1, doi:10.20944/preprints202605.0768.v1.

11. (dopkins2024ribosomalprofilingof pages 7-7): Nicholas Dopkins, Bhavya Singh, Stephanie Michael, Panpan Zhang, Jez L. Marston, Tongyi Fei, Manvendra Singh, Cedric Feschotte, Nicholas Collins, Matthew L. Bendall, and Douglas F. Nixon. Ribosomal profiling of human endogenous retroviruses in healthy tissues. BMC Genomics, Jan 2024. URL: https://doi.org/10.1186/s12864-023-09909-x, doi:10.1186/s12864-023-09909-x. This article has 13 citations and is from a peer-reviewed journal.

12. (stricker2023hervsandcancer—a pages 28-29): Erik Stricker, Erin C. Peckham-Gregory, and Michael E. Scheurer. Hervs and cancer—a comprehensive review of the relationship of human endogenous retroviruses and human cancers. Biomedicines, 11:936, Mar 2023. URL: https://doi.org/10.3390/biomedicines11030936, doi:10.3390/biomedicines11030936. This article has 58 citations.

13. (heidmann2017hemoanancestral pages 8-8): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

14. (timpona2018vsvvectorsas pages 38-43): J Timpona. Vsv vectors as vaccines for emerging viruses and as probes for entry pathways. Unknown journal, 2018.

15. (heidmann2017hemoanancestral media 5246bf31): Odile Heidmann, Anthony Béguin, Janio Paternina, Raphaël Berthier, Marc Deloger, Olivia Bawa, and Thierry Heidmann. Hemo, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. Proceedings of the National Academy of Sciences, 114:E6642-E6651, Jul 2017. URL: https://doi.org/10.1073/pnas.1702204114, doi:10.1073/pnas.1702204114. This article has 92 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
  

Citations

1. heidmann2017hemoanancestral pages 2-3
2. heidmann2017hemoanancestral pages 4-4
3. shimode2023acquisitionandexaptation pages 6-7
4. heidmann2017hemoanancestral pages 5-6
5. denner2026retrovirusinducedimmunosuppressiona pages 14-16
6. dopkins2024ribosomalprofilingof pages 7-7
7. heidmann2017hemoanancestral pages 1-1
8. timpona2018vsvvectorsas pages 38-43
9. heidmann2017hemoanancestral pages 8-9
10. heidmann2017hemoanancestral pages 4-5
11. heidmann2017hemoanancestral pages 6-7
12. heidmann2017hemoanancestral pages 8-8
13. https://doi.org/10.3390/biom13101482
14. https://doi.org/10.1186/s12864-023-09909-x
15. https://doi.org/10.3390/biomedicines11030936
16. https://doi.org/10.1073/pnas.1702204114
17. https://doi.org/10.1038/s41579-019-0189-2
18. https://doi.org/10.1073/pnas.1702204114,
19. https://doi.org/10.3390/biom13101482,
20. https://doi.org/10.20944/preprints202605.0768.v1,
21. https://doi.org/10.1186/s12864-023-09909-x,
22. https://doi.org/10.3390/biomedicines11030936,